$EQ

Equillium, Inc. (EQ) announced preclinical data presentations for its EQ504 program at the 7th International AHR Conference. The data highlights EQ504's potential in treating ulcerative colitis by modulating immune responses and promoting tissue repair. EQ504 is an investigational AhR modulator with a multi-modal mechanism of action. The posters will be available on Equillium's website post-presentation.

Equillium, Inc. (EQ) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Equillium Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights Phase 1 proof-of-mechanism study of EQ504 initiation expected in Q4 2026, with data expected approximately six months thereafter Cash and cash equivalents of $57.2 million expecte

Zedelmayer Christine (Sr. Vice President and COO) sold 14,584 shares of Equillium, Inc. (EQ) at $2.93 on 2026-06-05 under a Rule 10b5-1 trading plan.

Connelly Stephen (President and CSO) sold 230,975 shares of Equillium, Inc. (EQ) at an average of $3.13 ($2.94–$3.16, $0.72M total) across 2 trades over 2026-06-04 to 2026-06-05.

EQ Inc. (CVE:EQ) shares fell 3.2% on Monday, trading between C$0.92 and C$0.92 and closing at C$0.92 versus C$0.95 previously. About 2,074 shares changed hands, down 86% from average daily volume. The stock has a C$64.03M market cap and negative P/E (-46).

Equillium COO Christine Zedelmayer sold 9,821 shares on May 27 at an average $2.70, raising $26,516.70, according to an SEC filing. She still directly owned 62,586 shares afterward. The sale was executed under a Rule 10b5-1 plan. The article also notes additional insider sales on May 28 and March 13 and March 9.

Tom Penny (Principal Accounting Officer) sold 65,000 shares of Equillium, Inc. (EQ) at $2.95 ($0.19M total) on 2026-05-28 under a Rule 10b5-1 trading plan.

Equillium (NASDAQ:EQ) presented preclinical data linking aryl hydrocarbon receptor (AhR) activation to miR-124 induction, led by CSO Stephen Connelly. Using its AhR modulator EQ504 and Abivax’s obefazimod (ABX464), the company reported miR-124 induction in immune cells with AhR antagonism reducing it, alongside decreases in pro-inflammatory cytokines. ABX464 showed an AhR EC50 ~400 nM in reporter assays. Equillium said Phase 1 readouts will focus on colon tissue drug exposure (EC50–EC90) and CYP

LA JOLLA, Calif., Nov. 20, 2025 ( GLOBE NEWSWIRE ) -- Equillium, Inc. ( NASDAQ:EQ ) , a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that management will ...

LA JOLLA, Calif., Nov. 20, 2025 ( GLOBE NEWSWIRE ) -- Equillium, Inc. ( Nasdaq: EQ ) , a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that management will ...